US In Situ Hybridization

Date: Sep 05 2018
|
WinterGreen Research
|
Number of Pages: 242
|
Alternate Text Alternate Text Alternate Text Alternate Text
Category: Energy & Power

WinterGreen Research announces that it has published a new study In Situ Hybridization: Market Shares, Strategy, and Forecasts, Worldwide, 2018 to 2024. The 2018 study has 242 pages, 83 tables and figures. The leading vendors in the In Situ Hybridization industry have invested in high-quality technology and processes to develop leading edge capability to leverage single cell in tissue diagnostic markets. Worldwide markets are poised to achieve continuing growth as th diagnostic pprocedures provide a window into cancer and infectious disease diagnosis and treatment that has not been available hitherto.

In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024, Table of Contents, In Situ Hybridization: Executive Summary, The study is designed to give a comprehensive overview of the In Situ Hybridization market segment. Research represents a selection from the mountains of data available of the most relevant and cogent market materials, with selections made by the most senior analysts. Commentary on every aspect of the market from independent analysts creates an independent perspective in the evaluation of the market. In this manner the study presents a comprehensive overview of what is going on in this market, assisting managers with designing market strategies likely to succeed., , , , Table of Contents a, , Abstract: In Situ Hybridization Reagents Make It Possible To Visualize Expression Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue Morphology Information , 1, Table of Contents, 3, US In situ Hybridization Executive Summary, 15, In Situ Hybridization (ISH), 15, 1., United States In Situ Hybridization ISH Market Definition and Market Dynamics, 16, 1.1, US In situ Hybridization Market Overview, 16, 1.1.1, Antibody Challenges and Validation, 16, 1.2, Scope of In situ Hybridization in Inflammation, 17, 1.2.1, RNAscope® Applications, 17, 2., In-Situ Hybridization Market Shares and Market Forecasts, 20, 2.1, In-Situ Hybridization Market Driving Forces, 20, 2.1.1, Identification of Cytokines and their Cellular Origins, 21, 2.1.2, Detection of Long Non-Coding RNA (lncRNA) in Inflammatory Diseases, 21, 2.1.3, Role of Inflammatory Pathways During Carcinogenesis, 22, 2.1.4, Therapeutic Potential Of Secreted Proteins In Inflammatory Diseases, 22, 2.1.5, Dual ISH-IHC Detect Cytokines During Inflammatory Responses, 22, 2.2, In Situ Hybridization Market Shares, 24, 2.2.1, Roche, 25, 2.2.2, Abbott Molecular, 25, 2.2.3, Advanced Cell Diagnostics, 25, 2.2.4 PerkinElmer In Situ Hybridization Market Driving Forces, 26, 2.2.5, In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments, 27, 2.3, In Situ Hybridization Market Forecasts, 29, 2.3.5, In Situ Hybridization Market Segments, Units and Kits, Dollars and Percent, US,, 29, 2.4, In situ Hybridization Market Segments, 31, 2.4.1, In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017, 32, 2.4.2, Fluorescence (FISH) and Chromogenic (CISH) Detection, 33, 2.4.3, ISH Applications, 36, 2.4.4, Multiplex Fluorescence In Situ Hybridization (FISH), 36, 2.4.5, Fluorescence In Situ Hybridization (FISH), 37, 2.4.6, Cancer Drug Market, 40, 2.4.7, Chronic Lymphocytic Leukemia (CLL), 40, 2.4.8, In-Situ Hybridization Cancer Diagnosis, Cytology, Infectious Disease Molecular Diagnostic, 42, 2.1.6, In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, 47, 2.5, In-Situ Hybridization Pricing, 54, 2.5.1, miRCURY LNA miRNA Detection Probes, 54, 2.5.2, Price and Availability, 58, 2.6, In-Situ Hybridization Geographical Analysis, 61, 3, In-Situ Hybridization Research and Technology, 68, 3.1, Hybridization Technique, 68, 4, In-Situ Hybridization Company Profiles, 69, 4.1, Abbott Laboratories, 69, 4.1.1, Abbott Laboratories Market Categorization, 69, 4.1.2, In Situ Hybridization Product Category, Application and Specification, 70, 4.1.3, Abbott Laboratories Vysis Chronic Lymphocytic Leukemia (CLL) FISH Probe Kit (IVD), 71, 4.1.4, Vysis CLL FISH Probe Kit Contents, 72, 4.1.5, Acupath Laboratories Test For Detecting Bladder Cancer Uses Probes from Abbott Molecular, 74, 4.1.6, Abbott Laboratories Barrett’s Esophagus FISH, 75, 4.1.7, Abbott Molecular Vysis CLL FISH Probe Kit |, 77, 4.1.8, Abbott Laboratories Revenue, 77, 4.1.9, Abbott Laboratories ThermoBrite System, 81, 4.1.10, Abbott Laboratories User Programmable Settings, 82, 4.1.11, Abbott Laboratories Vysis FISH Chromosome Search, 83, 4.1.12, Abbott Laboratories Molecular Diagnostics, 84, 4.1.13, Abbott Diagnostic Products, 85, 4.2, Acupath Laboratories, 87, 4.2.1, Acupath Laboratories Barrett’s Esophagus FISH, 88, 4.3, Agilent Technologies, 88, 4.3.1, Agilent CGH & CGH+SNP Microarrays, 91, 4.3.2, Agilent Technologies Revenue, 91, 4.3.3, Agilent Diagnostics and Genomics, 93, 4.4, Bio-Techne / ACD, 96, 4.4.1, Bio-Techne ACD RNAscope Widely Used In-Situ Hybridization Technique, 97, 4.4.2, Bio-Techne Revenue, 98, 4.4.3, Biotechne US Regional Analysis, 101, 4.4.4, Advanced Cell Diagnostics, 102, 4.5, F. Hoffmann-La Roche AG, 102, 4.5.1, Roche Gene Amplification by Fluorescence In Situ Hybridization, 104, 4.5.2, Roche Automated RNA isolation, 105, 4.5.3, Roche Fluorescence In Situ Hybridization (FISH), 105, 4.5.4, Roche Agreement with Merck Millipore Sigma, 106, 4.5.5, Roche Immuno Diagnostics, 108, 4.5.6, F. Hoffmann-La Roche AG Revenue, 109, 4.5.7, Roche Buys Flatiron Health Leader In Oncology-Specific Electronic Health Record (EHR) Software, 114, 4.6, Danaher / Leica Biosystems Nussloch GmbH, 115, 4.6.1, Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments, 116, 4.6.2, Leica Biosystems Nussloch GmbH Revenue, 122, 4.6.3, Danaher Geographical Revenue, 124, 4.7, Thermo Fisher Scientific, 125, 4.7.1, Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH), 125, 4.7.2, Chromogenic In Situ Hybridization (CISH), 128, 4.7.3, Thermo Fisher Scientific Revenue, 133, 4.8, Merck KGaA, 134, 4.9, PerkinElmer, 135, 4.9.1, PerkinElmer Stain, 144, 4.9.2, Perkin Elmer Revenue, 146, 4.10, Qiagen / Exiqon A/S, 150, 4.10.1, Qiagen’s GeneReader NGS System, 153, 4.10.2, Polygenetic Mutations Drive Cancer, 153, 4.10.3, Qiagen Revenue, 154, 4.11, BioGenex Laboratories, 155, 4.11.1, BioGenex Fully-Automated Molecular Pathology Workstation, 156, 4.11.2, BioGenex Boosts Genome Research and Diagnostics - BioGenex US, 159, 4.11.3, BioGenex Antibodies for Cancer Diagnosis, 161, 4.11.4, BioGenex PMS2, 161, CK5, 162, 4.11.5, eFISHiency System for the Analysis of Solid Tumors - BioGenex US, 163, 4.12, Bio SB, 165, 4.12.1, Bio SB Zytovision Molecular Diagnostics, 165, 4.13, Bio-Techne / Advanced Cell Diagnostics (ACD), 167, 5, Summary and Conclusions, 172, 5.1, Analyze A Marker At The Single Cell Level, 172, 5.2, Advances in RNA In Situ Hybridization, 172, 6, Appendix A: List Of Nucleic Acid-Based Tests, 173, 6.1, List: Nucleic Acid-Based Tests Approved by US Center for Devices and Radiological Health, 173, 6.1.1, List of Human Genetic Tests, 174, 6.1.2, List of Microbial Tests, 191, 6.2, In Vitro Diagnostics, 233, WinterGreen Research,, 235, WinterGreen Research Methodology, 236, WinterGreen Research Process, 237, Market Research Study, 238, WinterGreen Research Global Market Intelligence Company, 239, , , Abstract: In Situ Hybridization Reagents Make It Possible To Visualize Expression Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue Morphology Information , 1, Figure 1., In Situ Hybridization Market Shares, Dollars, US, 2016 and 2017, 24, Figure 2., In Situ Hybridization Market Driving Forces, 26, Figure 3., In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017, 27, Figure 4., In Situ Hybridization Market Shares, $ per Unit and $ per Kit, Dollars and Percent, US, 2017, 28, Figure 5., In Situ Hybridization Market Segments, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017, 29, Figure 6., In Situ Hybridization Market Segments, $ per Unit and $ per Kit, Dollars and Percent, US, 2017, 30, Figure 7., In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017, 32, Figure 8., In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2012 to 2017, 33, Figure 9., In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2017 to 2024, 34, Figure 10., Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods, 35, Figure 11., Diagnostics Growth, 42, Figure 12., In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Dollars, US, 2012 to 2017, 43, Figure 13., In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Dollars, US, 2017 to 2024, 44, Figure 14., In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Percent, US, 2017 to 2024, 45, Figure 15., In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Percent, US, 2012 to 2017, 45, Figure 16., In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2012 to 2017, 47, Figure 17., In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2017 to 2024, 48, Figure 18., In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2012 to 2017, 49, Figure 19., In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2017 to 2024, 50, Figure 20., 575 Million People with Autoimmune Disease, 51, Figure 21., PerkinElmer Assays for Autoimmune Disease, 52, Figure 22., PerkinElmer Diagnostics, 53, Figure 23., PerkinElmer In Situ Hybridization, 57, Figure 24., In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2012 – 2017, 63, Figure 25., In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2017 - 2024, 65, Figure 26., Abbott Laboratories Vysis CLL FISH Probe Kit Probe Info, 71, Figure 27., Abbott Laboratories Vysis CLL FISH Probe Kit Contents, 72, Figure 28., Abbott Laboratories Vysis CLL FISH Probe Kit includes LSI, 72, Figure 29., Abbott Vysis CLL FISH Probe Kit, 73, Figure 30., Abbott Laboratories Segment Sales, 2017, 78, Figure 31., Abbott Segment Sales 2015-2017, 79, Figure 32., Abbott Geographical Revenue, 80, Figure 33., Abbott Laboratories ThermoBrite System, 81, Figure 34., Abbott Laboratories ThermoBrite System Functions, 82, Figure 35., Abbott Laboratories Molecular Testing, 84, Figure 36., Abbott Diagnostic Product Target Markets, 85, Figure 37., Abbott Diagnostic Principal Products, 86, Figure 38., In Situ Hybridization Detection System: Agilent Product Area: Standard Nucleic Acid Detection System, 88, Figure 39., PNA ISH Detection Kit Product Area: PNA Probes & Detection System, 90, Figure 40., Roche RNA Isolation Kit, 105, Figure 41., Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings, 107, Figure 42., Key points of the Roche Merc agreement include:, 107, Figure 43., Roche Immuno Diagnostics DISCOVERY XT, 108, Figure 44., Roche DISCOVERY XT Research Instrument Functions, 109, Figure 45., F. Hoffmann-La Roche AG Sales, 110, Figure 46., Roche by the Metrics, 112, Figure 47., F. Hoffmann-La Roche AG Pharmaceutical Sales, 113, Figure 48., Danaher Brands, 116, Figure 49., Leica Biosystems Bond III Technical Specifications, 117, Figure 50., Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments, 118, Figure 51., Leica SCN400 Slide Scanner Features, 119, Figure 52., Leica BOND Ready-To-Use Antibodies (No Mixing, Titration Or Dilution), 120, Figure 53., Leica Biosystems, 121, Figure 54., Danaher Segment Revenue, 123, Figure 55., Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) Positioning, 125, Figure 56., Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) In Situ Hybridization (ISH) Technologies, 126, Figure 57., Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods, 127, Figure 58., 5.7.1 Thermo Fisher Scientific EVOS Cell Imaging Systems, 129, Figure 59., Thermo Fisher Scientific Fluorescence Systems, 130, Figure 60., Thermo Fisher Scientific Cell Analysis, 131, Figure 61., Thermo Fisher Scientific Imaging Portfolio Components, 132, Figure 62., Thermo Fisher Scientific Revenue, 133, Figure 63., PerkinElmer In Situ Hybridization, 136, Figure 64., PerkinElmer In Situ Hybridization, 137, Figure 65., PerkinElmer In Situ Hybridization, 139, Figure 66., PerkinElmer Financials at a Glance, 140, Figure 67., PerkinElmer Diagnostics Revenue, 141, Figure 68., PerkinElmer in situ hybridization Expanding Diagnostics Market Reach and Global Impact, 142, Figure 69., PerkinElmer Diagnostics, 143, Figure 70., PerkinElmer Stain, 144, Figure 71., Perkin Elmer Revenue, 146, Figure 72., PerkinElmer offers Ultra-Sensitive And Specific Mirna Detection By In Situ Hybridization (ISH) Functions, 149, Figure 73., miRCURY LNA miRNA Detection Probes, 151, Figure 74., BioGenex Performance Systems, 156, Figure 75., BioGenex Product Areas, 157, Figure 76., BioGenex Performance Systems / BioGenex Flagship Products, 157, Figure 77., BioGenex Customers, 158, Figure 78., Figure: Colon Carcinoma stained with PMS2 (clone EP51),Staining in FFPE tisues, using DAB chromogen and BioGenex Polymer-HRP Detection System., 162, Figure 79., BioGenex Cervical Cancer Stained with Anti-Human CK-5 (clone EP24),Staining in FFPE Tissues, Using DAB Chromogen and Polymer-HRP Detection System, 163, Figure 80., BioGenex Fish Steps Reduction, 164, Figure 81., BioGenex eFISHiency System Reduces Hands-On Processing Time To 30 Minutes, 165, Figure 82., Bio SB Zytovision Molecular Diagnostics, 165, Figure 83., Bio-Techne / ACD, 170, , , www.wintergreenresearch.com, (781) 863-5078, , , , , , , , , , , ,

No Content

Electronic files(PDF) of market research reports will be dispatched within 12 to 24 hours. (Mon-Fri IST)

Select License Type

Need Help?
+
SUBSCRIBE TO THE MAILING TO KEEP UP WITH LATEST NEWS AND UPDATES
x
We use cookies to deliver the best possible experience on our website by improving the user experience, personalizing your visit, and compiling aggregate statistics. By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more visit our Privacy policy page.